BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

• Status: Recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Illinois at Chicago
• Treatments: Antiemetics; BB 1101; Dexamethasone; Dexamethasone acetate; Granisetron; Ondansetron

Criteria

Inclusion Criteria:

• Age 18-75 years at time of enrollment receiving either a preparative regimen and either an autologous or allogeneic stem cell transplant.

• No vomiting ≤ 24 hours prior to registration

• No treatment with an antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for ≤ 30 days' prior registration or planned during protocol therapy. No patients will be removed from these treatments for study enrollment purposes.

• No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue antiemetic therapy). No patients will be removed from these treatments for study enrollment purposes.

• No known hypersensitivity to granisetron

Exclusion Criteria:

• Concurrent use of amifostine

• Known hypersensitivity to granisetron patch or ondansetron

• Patients with a history of long QT syndrome or Torsade de Pointes